This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.
Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod
by Zacks Equity Research
Emergent's (EBS) shares rise as its anthrax vaccine, Cyfendus (AV7909), gets FDA approval, offering preventive measures for people aged 18 to 65, who were exposed to the harmful bacillus anthracis germ.
Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug
by Zacks Equity Research
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
by Zacks Equity Research
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.
Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets
by Zacks Equity Research
Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.
Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study
by Zacks Equity Research
Theseus (THRX) announces the discontinuation of enrollment in its phase I/II study of THE-630 in patients with gastrointestinal stromal tumors due to observed adverse reactions. The stock falls 72%.
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.
Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study
by Zacks Equity Research
Halozyme (HALO) rises 5% after Roche's late-stage multiple sclerosis study of subcutaneous co-formulation of Ocrevus developed with its Enhanze technology meets goals.
ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
ADC Therapeutics SA (ADCT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Acadia (ACAD) Expands Existing Licensing Deal With Neuren
by Zacks Equity Research
Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidate.
After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study
by Zacks Equity Research
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
by Zacks Equity Research
Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.
Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%
by Zacks Equity Research
Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
by Zacks Equity Research
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
by Zacks Equity Research
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
by Zacks Equity Research
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Down -36.18% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
by Zacks Equity Research
ADC Therapeutics SA (ADCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.